Tavneos
(Avacopan)ApprovedSmall molecule
AmgenAvacopan is used to treat rare autoimmune diseases where the body's immune system attacks blood vessels, potentially damaging organs like the heart and lungs. It works by blocking a specific part of the immune system that causes this blood vessel damage.[2] Tavneos is currently approved and in use across 4 indications[4].[1]
Tavneos is one of 111 small molecule programs targeting Granulomatosis with Polyangiitis. It is currently in Approved.
4
Indications
13
Total Trials
6
Active Trials
110
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
131 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPhase 3
Tavneos
AmgenApproved
Zemplar
AbbViePhase 3
Simulect
NovartisPhase 3
Ultomiris
AstraZenecaPhase 3
Acetadote
AArbor Pharmaceuticals, Inc.
Phase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Epoetin Beta
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ANCA-Associated Vasculitis3 trials
Granulomatosis with Polyangiitis1 trial
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Not yet recruiting·—·Phase 2/3·NCT07176546·30 enrolled
Children1 trial
6 more indications
Hidradenitis Suppurativa1 trial
Single Dose1 trial
End Stage Renal Disease (ESRD)1 trial
ART1 trial
Regulatory
FDA Approval Timeline[5]
Oct 7, 2021
TAVNEOS
NDA NDA214487
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tavneos drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Avacopan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]